SEC-sourced researchBeta
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0000879407
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 5/6
- Filing date
- Nov 25, 2025
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| September 2023 | 240,735,000.0000 | Nov 25, 2025 |
| September 2024 | 3,551,000.0000 | Nov 25, 2025 |
| September 2025 | 829,448,000.0000 | Nov 25, 2025 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| September 2025 | 829,448,000.0000 | -1,631,000.0000 | 179,552,000.0000 | 1,385,295,000.0000 | — | Nov 25, 2025 |
| September 2024 | 3,551,000.0000 | -599,493,000.0000 | -462,851,000.0000 | 1,139,802,000.0000 | — | Nov 25, 2025 |
| September 2023 | 240,735,000.0000 | -205,275,000.0000 | -153,890,000.0000 | — | — | Nov 25, 2025 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $829.45M | September 2025 | Nov 25, 2025 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.55M | September 2024 | Nov 25, 2025 | 10-K |
| Net incomeNetIncomeLoss | -$1.63M | September 2025 | Nov 25, 2025 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $179.55M | September 2025 | Nov 25, 2025 | 10-K |
| Total assetsAssets | $1.39B | September 2025 | Nov 25, 2025 | 10-K |
| Total liabilities | — | — | — | — |